Re. Denosumab MTA

I would make the following comments;

1. I consider that all the relevant information has been taken into account.

2. I consider all the summaries of clinical and cost effectiveness to be reasonable interpretations of the evidence.

3. I consider the provisional recommendations to be sound and a suitable basis for guidance to the NHS with the following caveat:

1.1 and 1.2:

While I accept that these recommendations are based on the published evidence including the NICE Prostate Cancer guidance there is a difference between the 2 tumour sites which could be (wrongly) attributed to discrimination. I would be keen to see acknowledgment of future modification to the guidelines in light of further evidence in Prostate cancer.

4. I can see no issue relating to potential discrimination on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?

Yours Sincerely

Dr. David Dodds